Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer

Gynecologic Oncology

Volumn 114, Issue 2, 2009, Pages 246-252

  Karam, Amer K ^a   Chiang, Jing Wang ^b   Fung, Ewina ^c   Nossov, Vladimir ^a   Karlan, Beth Y ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Adjuvant chemotherapy; Cytoreductive surgery; Neoplasm drug resistance; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SENESCENCE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67549146391     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.02.022     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 2 (2008 March 1) 71-96
2. Fung-Kee-Fung M., Oliver T., Elit L., Oza A., Hirte H.W., and Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr. Oncol. 14 5 (2007 Oct) 195-208
3. Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., and Barrett R.J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 12 9 (1994 Sep) 1748-1753
4. Gore M.E., Fryatt I., Wiltshaw E., and Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36 2 (1990 Feb) 207-211
5. Markman M., Webster K., Zanotti K., Rohl J., and Belinson J. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol. Oncol. 93 2 (2004 May) 390-393
6. Schrag D., Garewal H.S., Burstein H.J., Samson D.J., Von Hoff D.D., and Somerfield M.R. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 22 17 (2004 Sep 1) 3631-3638
7. Kern D.H., and Weisenthal L.M. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J. Natl. Cancer Inst. 82 7 (1990 Apr 4) 582-588
8. Markman M. Chemosensitivity and chemoresistance testing. J. Clin. Oncol. 23 29 (2005 Oct 10) 7363-7364
9. Samson D.J., Seidenfeld J., Ziegler K., and Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J. Clin. Oncol. 22 17 (2004 Sep 1) 3618-3630
10. Kern D.H., Drogemuller C.R., Kennedy M.C., Hildebrand-Zanki S.U., Tanigawa N., and Sondak V.K. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res. 45 11 Pt 1 (1985 Nov) 5436-5441
11. Chi D.S., McCaughty K., Diaz J.P., Huh J., Schwabenbauer S., Hummer A.J., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 9 (2006 May 1) 1933-1939
12. Salani R., Santillan A., Zahurak M.L., Giuntoli II R.L., Gardner G.J., Armstrong D.K., et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109 4 (2007 Feb 15) 685-691
13. Winter III W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 25 24 (2007 Aug 20) 3621-3627
14. Segna R.A., Dottino P.R., Mandeli J.P., Konsker K., and Cohen C.J. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J. Clin. Oncol. 11 3 (1993 Mar) 434-439
15. Munkarah A.R., and Coleman R.L. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol. Oncol. 95 2 (2004 Nov) 273-280
16. Eisenkop S.M., Friedman R.L., and Spirtos N.M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88 1 (2000 Jan 1) 144-153
17. Eltabbakh G.H. Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma. J. Surg. Oncol. 73 3 (2000 Mar) 148-152
18. Eltabbakh G.H., Piver M.S., Hempling R.E., Recio F.O., Lele S.B., Marchetti D.L., et al. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol. Oncol. 70 3 (1998 Sep) 392-397
19. Loizzi V., Chan J.K., Osann K., Cappuccini F., DiSaia P.J., and Berman M.L. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am. J. Obstet. Gynecol. 189 5 (2003 Nov) 1301-1307
20. Benedetti Panici P., De Vivo A., Bellati F., Manci N., Perniola G., Basile S., et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann. Surg. Oncol. 14 3 (2007 Mar) 1136-1142
21. Santillan A., Karam A.K., Li A.J., Giuntoli II R., Gardner G.J., Cass I., et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol. Oncol. 104 3 (2007 Mar) 686-690
22. Tebes S.J., Sayer R.A., Palmer J.M., Tebes C.C., Martino M.A., and Hoffman M.S. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 106 3 (2007 Sep) 482-487
23. DeVita V.T., Hellman S., and Rosenberg S.A. Cancer, principles and practice of oncology. 6th ed. (2001), Lippincott Williams & Wilkins, Philadelphia
24. Geisler J.P., Linnemeier G.C., Thomas A.J., and Manahan K.J. Extreme drug resistance is common after prior exposure to paclitaxel. Gynecol. Oncol. 106 3 (2007 Sep) 538-540
25. McAlpine J.N., Eisenkop S.M., and Spirtos N.M. Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecol. Oncol. 110 3 (2008 Sep) 360-364
26. O'Reilly S., Fleming G.F., Barker S.D., Walczak J.R., Bookman M.A., McGuire III W.P., et al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J. Clin. Oncol. 15 1 (1997 Jan) 177-186
27. Cortazar P., Gazdar A.F., Woods E., Russell E., Steinberg S.M., Williams J., et al. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin. Cancer Res. 3 5 (1997 May) 741-747
28. Shaw G.L., Gazdar A.F., Phelps R., Linnoila R.I., Ihde D.C., Johnson B.E., et al. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res. 53 21 (1993 Nov 1) 5181-5187
29. Shaw G.L., Gazdar A.F., Phelps R., Steinberg S.M., Linnoila R.I., Johnson B.E., et al. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J. Cell. Biochem., Suppl. 24 (1996) 173-185
30. Berchuck A., Iversen E.S., Lancaster J.M., Pittman J., Luo J., Lee P., et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin. Cancer Res. 11 10 (2005 May 15) 3686-3696
31. Spentzos D., Levine D.A., Kolia S., Otu H., Boyd J., Libermann T.A., et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J. Clin. Oncol. 23 31 (2005 Nov 1) 7911-7918
32. Spentzos D., Levine D.A., Ramoni M.F., Joseph M., Gu X., Boyd J., et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J. Clin. Oncol. 22 23 (2004 Dec 1) 4700-4710
33. Chang J.C., Wooten E.C., Tsimelzon A., Hilsenbeck S.G., Gutierrez M.C., Elledge R., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 9381 (2003 Aug 2) 362-369
34. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346 25 (2002 Jun 20) 1937-1947
35. Maenpaa J.U., Heinonen E., Hinkka S.M., Karnani P., Klemi P.J., Korpijaakko T.A., et al. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial. Gynecol Oncol 57 3 (1995) 294-298
36. Kurbacher C.M., Cree I.A., Bruckner H.W., Brenne U., Kurbacher J.A., Muller K., et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugsl 9 1 (1998) 51-57
37. Cree I.A., Kurbacher C.M., Lamont A., Hindley A.C., and Love S. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 18 9 (2007) 1093-1101.